ASCELIA PHARMA ABASCELIA PHARMA ABASCELIA PHARMA AB

ASCELIA PHARMA AB

No trades
See on Supercharts

ACE fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. It offers the following clinical stage product candidates: Mangoral, a liver imaging drug being developed for detection and localization of potential liver metastases; and Oncoral, a tablet-based formulation of the chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric cancer. The company was founded on May 17, 1999, and is headquartered in Malmö, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ACE does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company